Filter By
Search
-
-
AGREEMENT ON A FRIENDLY TAKEOVER BID BY ONCODNA FOR INTEGRAGEN
Agreement to a friendly takeover bid initiated by ONCODNA for INTEGRAGEN at a price...
-
INTEGRAGEN - S1 2020 SALES OF €4.7M UP +13 % AND CASH POSITION OF €5.8M
IntegraGen today announces its unaudited sales figures for the first half of 2020. The sales...
-
INTEGRAGEN ACHIEVES CE MARKING FOR MERCURY™, A CLOUD-BASED SOFTWARE APPLICATION FOR INTERPRETING MOLECULAR DATA FROM CANCER PATIENTS' TUMORS
IntegraGen announces the CE marking of its cloud-hosted online software application,...
-
INTEGRAGEN UPDATE - ALWAYS OPEN FOR YOUR PROJECTS
IntegraGen is following government recommendations and precautionary measures related to the...
-
INTEGRAGEN - ANNUAL RESULTS 2019
Sales growth (+201TP3Q), EBITDA positive in the second half and close to...
-
INTEGRAGEN ANNOUNCES AN AGREEMENT WITH A LEADING US CANCER CENTER FOR THE USE OF MERCURY™, THE ONCOLOGY SEQUENCING DATA INTERPRETATION AND REPORTING TOOL
IntegraGen announced today that the Dana Farber Cancer Institute will use MERCURYTM, IntegraGen's proprietary software, to...
-
COVID-19: MEASURES TO PROTECT EVERYONE AND ENSURE YOUR PROJECTS RUN SMOOTHLY
Dear IntegraGen customers and partners, We care about your satisfaction and understand that all...
-
INTEGRAGEN RENEWS PARTNERSHIP AGREEMENT WITH INSTITUT PASTEUR FOR HIGH THROUGHPUT SEQUENCING IN MICROBIOLOGY
IntegraGen today announced the renewal, until December 2021, of its partnership agreement with the Institut Pasteur...
-
INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018
Analysis of samples from the PETACC 8 phase III clinical trial shows that the...
